Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
Novartis shares experienced their worst single-day drop in over two decades following the failure of a crucial phase 3 trial for an Avidity buyout drug.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Novartis is facing significant financial and strategic turbulence after a centerpiece RNA drug intended for the treatment of a rare muscle disease failed a crucial phase 3 study. This clinical setback has resulted in a sharp slide for NVS stock, which according to Yahoo Finance, clocked its worst day in over 20 years. This event marks a period of intense volatility for the company, as the failed study occurred amidst a broader series of clinical disappointments for the organization. Coverage from BioPharma Dive, STAT, and Yahoo Finance emphasizes that this is not an isolated incident, but rather the second trial failure Novartis has encountered within a single week. STAT reports that the failure of the neuromuscular drug adds substantial pressure to the company's overall pipeline.
This pattern of setbacks has shifted the narrative toward the leadership of the firm, with Yahoo Finance explicitly noting that these twin drug setbacks are piling pressure on both the company's pipeline and its CEO. Bloomberg has further highlighted the stock slide, listing Novartis alongside Boston Scientific as a security to watch during this downward trend. To understand the gravity of this situation, it is necessary to recognize the scale of the investment and the specific nature of the drug. The product in question is an RNA-based therapy targeting rare muscle diseases, a high-stakes area of biotechnology. The severity of the market reaction, evidenced by the 20-year low in daily performance, indicates that investors had priced in a high probability of success for this specific neuromuscular treatment.
Moving forward, market observers are monitoring the ripple effects within the biotechnology sector. While the primary focus remains on the Novartis pipeline and the stability of its leadership, other companies are seeing unconfirmed volatility. For instance, Yahoo Finance reported that Dyne Therapeutics shares fell 31% in premarket trading, although the coverage noted that no catalyst for this specific drop has been confirmed. Future developments will likely center on how Novartis manages its pipeline pressure and whether further updates regarding the Avidity buyout or the failed RNA drug trials are released to the public.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 68d ago.
Quick answers
Why did Novartis stock drop significantly?
The stock experienced its worst day in over 20 years after a centerpiece RNA drug for a rare muscle disease failed a crucial phase 3 study.
What is the financial scale of the buyout involved?
The drug was part of a $12 billion Avidity buyout.
How many trials has Novartis failed recently?
According to Yahoo Finance, this was the second trial failure the company experienced in a single week.
Coverage (6)
- NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week Yahoo Finance · 71d ago
- Novartis RNA drug falls short in rare muscle disease study BioPharma Dive · 71d ago
- Novartis twin drug setbacks pile pressure on pipeline and CEO Yahoo Finance · 71d ago
- Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed Yahoo Finance · 71d ago
- Watch Novartis and Boston Scientific Slide, Intel Price Hikes bloomberg.com · 71d ago
- Neuromuscular drug from Novartis fails in key study, adding to pressure on company STAT · 71d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.